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During this century, cancer has become one of the major problem and diseases which has
caused predominant death and it will even surpass heart diseases. Many of the researchers
begin to use the term lifetime risk for cancer patients which refer to the time that cancer will
progress and developed or the time that the patient will die because of cancer. There are many
problems (i.e., side effects) associated with cancer diseases either solid type or hematological
type such as nausea, vomiting, diarrhea, constipation, hypercalcemia, pain, lost of appetite,
anemia, fatigue, cachexia, leucopenia, neutropenia and thrombocytopenia. However the major
problems are nausea and vomiting, neutropenia, anemia, thrombocytopenia and hypercalce‐
mia. Hence due to these reasons cancer is consider as one of the major diseases that will effect
on the quality of life for human [1-6].
1.2. Chemotherapy background
Chemotherapy was developed and used since the Word War I from the chemical weapon
program of the United State of America (USA). Since then chemotherapy has became as one
of the most important and significant treatment of cancer. Its main mechanism of action is by
destroying the cancer cells which are characterized by their high multiplication and growth
speed. However when comparing chemotherapy with other types of treatments, it still remain
potentially high risk with many side effects which are difficult to manage. Chemotherapy used
required the involvement of various clinical professionals during its various stages of admin‐
istration and enormous patient health care is needed to overcome its side effects [7-8].
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1.3. Chemotherapy side effects
The goal of chemotherapy is to be as effective as possible with tolerable side effects, since the
dose of chemotherapy will be toxic to the cancer cells as well as to the normal cells. A proportion
of the cancer patients suffer from only mild side effects whereas others may suffer from serious
side effects. These side effects are classified as:
1. Acute, which develop within 24 hours after chemotherapy administration.
2. Delayed, which developed after 24 hours and up to 6 to 8 weeks after chemotherapy
treatments.
3. Short term, combination of both acute and delayed effect.
4. Late/ long term, which developed after months or years of chemotherapy treatment.
5. Expected, which developed among 75% of the patients.
6. Common, occurred in 25%-75% of the patients.
7. Uncommon, happened is less than 15% of the patients.
8. Rare, occur in only 5% of the patients.
9. Very rare, occur with less than 1% of the patients.
Occurrence of specific side effects will vary according to the chemotherapy or medications
used. The most common side effects experienced are nausea and vomiting, anemia, hair lost,
bleeding (thrombocytopenia), hyperuricemia, neurotoxicity, cardiotoxicity, bone marrow
depression, alopecia, nephrotoxicity, pulmonary toxicity, dehydration, cystitis and mucositis.
So different parameters must be taken into consideration to prevent, reduce and overcome
these side effects [8-10]. This chapter will focus on the main side effects caused by cancer
disease and/ or chemotherapy.
2. Main problems caused by cancer disease itself and/ or chemotherapy
treatment
2.1. Nausea and vomiting
Both nausea and vomiting are recognized as two separate and distinct conditions. Nausea is
an unpleasant sensation of being vomit or urge to vomit which may or may not result in
vomiting. While, vomiting or emesis is the process of expelling of undigested food through
the mouth. Nausea and vomiting can arises from different or wide spectrum of etiologies which
are either directly associated to cancer disease itself or to its treatment. According to the new
ranking of chemotherapy side effects, nausea is the number one or the most disturbing side
effect while vomiting is the third and sometimes the fifth disturbing chemotherapy side effects.
Even so, not all cancer patients suffer from nausea and/ or vomiting because not all of them
were treated with emetogenic chemotherapy [11-17].
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2.1.1. Nausea and vomiting in solid cancer patients
Nausea and vomiting are two of the major problems that are associated with cancer patients
and 50%-55% of cancer patients suffer from both nausea and vomiting even with the use of
antiemetic drugs. The main causes for this are either due to the chemotherapy or because of
the cancer progression. Some of the cancer patients who were treated with chemotherapy did
not suffer from nausea or vomiting because the chemotherapy used were not significantly
emetogenic. Nausea and vomiting still remain the major side effects that occur and are
associated with chemotherapy and cancer diseases [11, 18-20].
2.1.2. Understanding nausea and vomiting in advanced solid cancer
Both nausea and vomiting are very common problems especially with advanced stages of solid
cancer diseases like breast cancer and stomach cancer where 50 to 60% of the patients are
mainly female under 65 years of age [21]. In this situation, nausea and vomiting occur because
of the advanced stages of solid cancer diseases characterized by more severe complications
than that caused by chemoradiotherapy or other treatments. The main causes for those
problems are gastric stasis, obstruction of the intestine, opioid use, constipation caused by
morphine uses, hypercalcemia, brain metastasis, renal failure, hyponatremia, increases in the
intracranial pressure and tumor burden [21].
2.1.3. Pathophysiology of chemotherapy-induced nausea and vomiting
Chemotherapy cause nausea by stimulating the autonomic nervous system (ANS), while
vomiting  is  triggered  when  afferent  impulses  from  chemoreceptor  trigger  zone  (CTZ),
pharynx, cerebral cortex and vagal afferent fiber stimulate the vomiting center (VC) located
in the medulla. The stimulation of the VC leads to contraction of muscles of abdomen, chest
wall and diaphragm, so this will  lead to an expulsion of stomach and intestine contents
[11-20]. The main mechanism of chemotherapy induced vomiting is the stimulation of the
entrochromaffin  cells  lining the wall  of  the  gastrointestinal  tract  (GIT)  hence causes  the
release of  the serotonin.  The serotonin will  then bind to the vagal  afferent 5-HT3  recep‐
tors in the GIT which will send impulses to the CTZ and VC. Vomiting will be triggered
when afferent impulses from CTZ, pharynx, cerebral cortex and vagal afferent fiber transfer
impulses to the VC [22].
2.1.4. Major patients risk factors related with nausea and vomiting
1- Gender, 2-Age, 3- History of motion sickness and history of vomiting during pregnancy, 4-
History of drinking alcohol, 5-Patient anxiety [11, 16, 18, 23-25]
2.1.5. Major chemotherapy factors responsible for incidence of nausea and vomiting
There are several chemotherapeutics factors that play a major role in the incidence and severity
of both nausea and vomiting which are:
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1- Emetogenic potential of the drug, 2- Dosage level, 3- Schedule of administration, 4- Route
of administration, 5- History of previous chemotherapy, 6- Rate of I.V infusion [11, 16, 18,
23, 26].
2.1.6. Classification of chemotherapy induced nausea and vomiting
This classification is based on the emetogenic potential of the chemotherapeutic drug.
1. Severe (90% of the patients will experience nausea and vomiting) Example: Carmustine
I.V ≥ 250 mg/ m2, Cisplatin I.V ≥ 50 mg/ m2, Cyclophosphamide I.V > 1500 mg/ m2,
Dacarbazine, Mechlorethamine, Nitrogen mustard and Streptozocin.
2. High (60%-90%) Example: Carboplatin, Carmustine I.V ≤ 250 mg/ m2, Cisplatin I.V < 50
mg/ m2, Cyclophosphamide I.V 750 mg/ m2 to 1500 mg/ m2, Cytarabine I.V > 1gm/ m2,
Dactinomycin, Daunorubicin, Doxorubicin I.V > 60 mg/ m2, Irinotecan, Methotrexate I.V
> 1 gm/ m2 and Procarbazine PO dose.
3. Moderate (30%-60%) Example: Altretamine I.V PO dose, Asparginase, Cyclophospha‐
mide (I.V) ≤ 750 mg/ m2, Cyclophosphamide PO dose, Doxorubicin (I.V) 20 to 60 mg/ m2,
Epirubicin I.V, Idarubicin, Ifosfamide, Lomustine PO dose, Methotrexate (I.V) 250-1000
mg/ m2, Mitoxantrone (I.V) < 15 mg/ m2, Pemetrexed, Raltitrexed, Temozalamide and
Topotecan.
4. Low (10%-30%) Example: Aldesleukin, Amsacrine, Bortezomib, Capecitabine, PO dose,
Docetaxel, Doxorubicin liposomal, Etoposide all dose I.V or PO, Erlotrinib PO dose,
Fluorouracil, Gefitinib PO dose, Gemcitabine, Methotrexate (I.V) 50-250 mg/ m2, Mito‐
mycin, Paclitaxel, Porfimer, Teniposide and Trastuzumab.
5. Very low (less than 10%) Example: Bleomycin, Busulfan PO dose, Chlorambucil PO dose,
Cladribine, Fludaradine, Hydroxyurea PO dose, Interferon, Levamisole, Melphalan PO
dose, Methotrexate < 50mg/ m2, Rituximab, Thalidomide, Thioguanine, Thiotepa, Vin‐
blastine, Vincristine, Vinorelbine and Vindesine [25, 27].
2.1.7. Classification and incidence of chemotherapy induced nausea and vomiting
CINV are clinically classified as:
1- Acute chemotherapy related nausea and vomiting, 2- Delayed emesis, 3- Anticipatory
emesis [11, 16, 18, 28].
2.1.8. Nausea and vomiting treatment options
The main goal of the antiemetic treatment is to abolish nausea and vomiting which in the
last  twenty years  consider  as  an inevitable  chemotherapy side effect.  This  prevention is
focused on the entire period of emetic risk which is 4 days for patients who received highly
or  moderately  emetogenic  chemotherapy  [22,  29].  This  could  be  perfectly  achieved  by
understanding the mechanisms of these antiemetic drugs either alone or in combination
so as to get  their  maximum benefit  [30].  Modern antiemetic treatments help in prevent‐
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ing 70%-80% of nausea and vomiting problems. Combination antiemetic treatment becomes
the standard regimen used for the control of nausea and vomiting caused by chemothera‐
py [30]. The different types of treatments are as follows: Serotonin-receptor antagonists (5-
HT3), Dopamine-2-receptor antagonists, Corticosteroids, Neurokinin-1-recptor antagonists,
Cannabinoids & Benzodiazepines [29].
2.1.9. Genetic polymorphism and incidence of nausea and vomiting
Interindividual diversity in drug metabolism is caused by many factors including environ‐
mental factors, cultural factors related with type of diet, concomitant drug therapy as well as
genetic factors i.e., ethnic variation. All of these variations play an important role in changing
pharmacokinetic and pharmacodynamic properties, volume of distribution, elimination,
disposition and clinical effect for many drugs [31, 32]. Much of this distinction has shown to
be caused by genetic polymorphisms of the human cytochrome P450 enzymes (CYP) [32]. CYP
is the most vital enzymatic system concerned with drug metabolism. Approximately 65% of
common drugs used are metabolized by cytochrome P450 enzymes and half of them are
mediated by the CYP3A subfamily [32].
2.2. Anemia
This is  a  condition characterized by lack of  blood or in other word a reduction of  total
quantity of erythrocyte (red blood cells, RBC) or hemoglobin in the circulation which are
necessary for normal function. This is caused by the inability of the bone marrow to replace
the erythrocyte lost. The normal level of RBC for the male is 5.4×106 cell/ µl and for female
is  4.8×106  cell/  µl  [11,  33-35].  It  is  considered as one of  the most frequent hematological
demonstration of malignant diseases, which will lead to momentous impairment in every
tissues  and  organs  of  cancer  patients  and  put  them  under  serious  stress.  This  major
problem may arise because of the underlining diseases (i.e., cancer diseases) or radiother‐
apy or chemotherapy treatment received [36, 37].
2.2.1. Red blood cell (RBC) and iron
The large proportion of body iron (20 mg per day) is used in the synthesis of erythrocyte cells.
The body absorbed about 1 mg of iron per day from the gut to compensate the amount of daily
iron lost. After the transition from erythroblast to reticulocyte, it will then remain for 3 to 4
days in the bone marrow after which being released into the blood circulation and circulate
for about 100-120 days. Red blood cell (RBC) has no mitochondria so are totally dependent on
ATP generated during glycolysis process. In the circulation RBC loss about 20% of its hemo‐
globin and shows physiological steps of aging. They will be phagocytes by the macrophage
leading to destruction of the erythrocyte and the removal of the iron from the hemoglobin (Hb)
which will be released into the plasma and redistributed again [38].
2.2.2. Types of anemia
There are different types of anemia as follows:
Supportive and Palliative Care in Solid Cancer Patients
http://dx.doi.org/10.5772/55358
491
1- Iron deficiency anemia, 2- Folic acid deficiency anemia, 3- Vitamin (Vit) B12 deficiency
anemia, 4- Vit C deficiency anemia, 5- Hemolytic anemia. It is an acquired type of anemia, 6-
Thalassemias, 7- Sickle cell anemia, 8- Anemia of chronic diseases (ACD) [36, 37].
2.2.3. Erythropoietin (EPO) description and action
EPO is a glycoprotein hormone consists of 165 amino acid with a peptide mass of 18.2 kDa. It
is mainly produce by the liver during fetal stage but after birth the kidneys become the primary
production sites. It has been realized that most of EPO in the circulation comes and produce
from the cortex of the kidney [39]. EPO production is mainly controlled by the feedback system
between kidney and bone marrow. The kidneys mainly depend on the renal oxygen sensor
for EPO production. Kidney cells response greatly towards hypoxia by increasing the EPO
production. Serum level of EPO ranges between 10 to 20 mU/ mL and for normal situation the
observed EPO concentration/ predictive EPO concentration (O/P) ratio must range between
0.8-1.2 [41]. EPO maintain erythropoiesis is by preventing the colony forming unit-erythroid
(CFU-E) from death by apoptosis process. By this way these progenitor cells will keep
proliferating and differentiating to produce erythrocyte [39].
2.2.4. Causes of anemia of chronic diseases (ACD)
Anemia remain as one of the serious and frequent problem of cancer mainly cancer of the
gastrointestinal, liver, head and neck, ovarian and cervix. This is mainly caused by cytokines
including interlukine-1, interlukine-6, interferon-γ and tumor necrosis factor-α produced by
these cancer diseases. These cytokines caused impairment of erythropoietin (EPO) synthesis,
reduce erythrocytes life span and prevent normal iron utilization. Other direct effect of tumor
that cause anemia is bone marrow replacement which is associated with inhibition of the body
ability for the production of RBC. This condition of bone marrow suppression is associated
with specific types of cancers like breast, prostate, myeloma, lymphoma and acute leukemia.
Also bone marrow suppression is mainly caused by chemotherapy and radiotherapy which
are the main treatment for cancer. Mainly in cancer patients the major risk factors responsible
for incidence and severity of anemia are the form of cancer as well as type and dose of
chemotherapy administered to the cancer patients. [11, 33-36, 40, 41].
2.2.5. Diagnosis of anemia
Several parameters need to be checked for anemia diagnosis since each one is considered
important and they are as follow: Family history, laboratory tests, X-ray, biopsy and bone
examination [33, 35, 42].
2.2.6. Grades of anemia (levels)
The grades or severity of anemia will depend on several factors like hemoglobin level, velocity
of onset of anemia, age, co-morbidities, extent of the underlining malignancy, intensity of
treatment and the biological function of the patients organ. Anemia grades as follows:
Normal level (women Hb= 12.0 g/ dL-16.0 g/ dL, men Hb= 14.0 g/ dL- 18.0 g/ dL)
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Mild Anemia Hb= 10g/ dL
Moderate Anemia Hb= 8.0 g/ dL- 10.0 g/ dL
Severe Anemia Hb= 6.5 g/ dL- 7.9 g/ dL
Life Threatening Anemia Hb= < 6.5 g/ dL [33, 36, 43].
2.2.7. Clinical signs and symptoms of anemia in cancer patients
The severity of signs and symptoms of anemia depend on several factors like Hb level, age,
extent of the underlining malignant, comorbidity, rate of anemia onset, biological activity of
patients vital organs and intensity of treatment used for anemia. Generally in elderly patients
the clinical signs and symptoms appear with Hb level higher than that in younger patients.
These symptoms usually appear gradually, starting with fatigue which is considered as one
of the major signs happing in 60% to more than 90% of the anemic patients. Lethargy and lost
of concentration will also take place as the Hb becomes lower than 12 g/ dL. When anemia
becomes severe and chronic this will lead to decompensation of cadiorespiratory and impair‐
ment of several body organs and activities [36, 46].
2.2.8. Role of cancer patients ages
It has been found that the incidence of anemia and cancer increases as the age of the patient
increases too. Anemia is much more related and significantly present as the age became higher
than 60 years old and with steeper increases after age 80 years. Many studies showed that the
hemoglobin levels remain stable between age 60 to 98 years old but there are several causes
for the high incidence of anemia in the old age since there were high comorbidity, hemato‐
poietic stress and reduce in function of many vital organs. For this reason there will be great
association and increases in occurrence of anemia in elderly patients [44].
2.2.9. Cancer patients gender and anemia
As mention above anemia highly occur in patients older than 60 years old, but it has been
found that among women, anemia happen at a younger age. The main difference between men
and women are the presence of menstrual cycle i.e., blood loss and childbearing iron loss which
make incidence and association of anemia higher in younger women as compared to men [44].
Besides that men and women who do not have menstruation, the amount of iron lost in one
day is 1 mg. While, in women still with menstrual, the loss is about 0.6 to 2.5 times more than
previous mentioned amount. The amount of iron lost during each menstruation cycle depends
on the severity of bleeding. The standard iron lost per menstrual cycle for woman weighting
about 60 kg is about 10 mg. So all of these evidences showed that anemia is associated with
female as a gender more than male [45].
2.2.10. Cancer patients race
Race also play an important role in incidence of anemia since it is consider as one of the risk
factor which play role in its occurrence. The prevalence of anemia in USA among white women
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is 7.1% and 25.1% among black women even after adjustment of iron level. Besides that black
women are characterized by lower mean hemoglobin level compared to white women. Also
black woman has a wide standard deviation in mean of hemoglobin than the white one has [45].
2.2.11. Mechanisms of anemia in cancer patients
2.2.11.1. Role of cancer disease
Occurrence and association of  anemia with cancer  depends on several  factors  including
patients  age,  stage  of  cancer,  presence  or  absence  of  infection  and  other  comorbidities.
Anemia prevalence is highly associated especially with lymphomas, genitourinary tumor,
lung and multiply myeloma. The incidence of mild to moderate anemia with solid tumor
is  higher  than incidence of  severe  anemia which occurs  highly  with hematological  can‐
cers than solid one [36, 46, 47]. The main mechanism whereby cancer causes anemia is by
producing cytokines which are mainly tumor necrosis factor (TNF-α) and interleukin-1 and
they have the ability to hamper EPO production and action, reduce the life span of RBC
and preclude ordinary utilization of iron. Other mechanisms which will cause association
of anemia with cancer will be separated from the cancer itself like Vit B12,  folic acid and
iron  deficiency.  Renal,  endocrinal  disorders  splenomegaly,  clonogenic  and  cachexia
occurrence with cancer also play a major role in occurrence of anemia [36].
2.2.11.2. Role of chemotherapy
Anemia is one of the common side effect of chemotherapy especially with the myelosuppres‐
sive type. Incidence and severity of anemia depend on several different factors which are the
chemotherapy type, schedule and intensity as well as type of cancer. Chemotherapy cycles
also play an important role in increasing the severity of anemia since multiply cycles will
cumulatively inhibit or reduce erythropoiesis. It has been found by the European Cancer
Anaemia Survey (ECAS) that the incidence of anemia after the first cycle is 19.5% and after
second cycle is 34.3% while after the third the incidence was more than 40%. Also single or
combination chemotherapy play a serious and major role in anemia incidence and severity
since the use of combination chemotherapy regimen will leads to severe anemia more than the
use of single chemotherapy drug [48-50]. Besides chemotherapy myelosuppression, anemia
can take place as a result of direct destruction of the RBC (i.e., direct effect on the erythropoiesis
in the bone marrow) or reduced erythropoietin production (i.e., impact on EPO production).
When this chemotherapy drug or other drugs used repetitively this may lead to prolong
production of anemia. Also the results that obtained from clinical trials showed that the
probability of mild anemia incidence after the use of chemotherapy is 100%, while the
probability of severe anemia incidence after chemotherapy is 80%. From these results and data
it has been proven that chemotherapy is the major impact factor for anemia onset and severity
in cancer patients [41, 48, 51-53].
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2.2.12. Indications and options for anemia treatments
Anemia and its related symptoms have serious negative effects on patients quality of life (QOL)
and anticancer treatment since it will leads to treatment delay. These effects may be tolerated
in young patients even with very low hemoglobin levels. While in patients with multimor‐
bidity would not be able to tolerate this and as a result of that many severe clinical signs and
symptoms will developed even with minor reduction in the Hb levels [36, 54, 55]. The treatment
strategies of anemia mainly based on the clinical situation, clinical signs and symptoms and
on the underlining cause of anemia. These treatments will include red blood cell transfusion,
corticosteroids, VitB12 and Epoetin alfa (recombinant human erythropoietin, rHuEPO). All
these treatments were used to overcome anemia related signs, symptoms and to improve the
anemic patients (QOL) [36].
2.3. Thrombocytopenia
Thrombocytopenia is a term used to denote abnormal decrease or drop in platelets numbers.
The main function of these platelets is clot formation during bleeding in order to prevent
blood lost. Thus a decrease in platelet number will leads to bleeding condition which ranges
from mild bleeding from small blood vessels to severe bleeding from large blood vessels.
Severe bleeding in the presence of severe thrombocytopenia or when is coupled with other
clotting disorders  can leads to  serious morbidity or  death.  Thrombocytopenia is  a  com‐
mon  problem  experience  by  cancer  patients,  which  usually  resulted  from  the  use  of
conventional  chemotherapy  and  at  times  is  a  dose  limiting  factor  for  chemotherapy
administration. The incidence of thrombocytopenia among solid cancer patients is rather
low i.e.,  ranging  between  10%-25% among breast  cancer,  ovarian  and  germ cell  cancer
patients  who  were  treated  with  intensive  chemotherapy.  However  thrombocytopenia
incidence is high among acute leukemia patients [56-63].
2.3.1. Platelets morphology and structure
Platelets or thrombocytes are irregular, disc shaped cells which are considered as the smallest
cells in the blood (0.5 to 3.0 µm diameter). They are usually produce from the megakaryocytes
which are large cells (80 to 150 µm diameter) found specifically in the spongy center of long
bones by the stimulation of thrombopoietin (TPO) by process called endomitosis whereby each
megakaryocyte cell produce about 2000 platelets. These platelets shared a characteristic of
having a very short life span (five to nine days only) so the bone marrow of healthy individual
continuously keep producing new platelets cells to replace the old dead ones. The thrombo‐
poietin hormone is mainly synthesis and produce by the liver and plays a major role in
stimulation of proliferation and maturation of platelets. The circulating platelets have no
nucleus but they have alpha granules and dense granules [57, 64, 65]. Physiologically the
platelets are removed from the blood circulation by two mechanisms. The first is being used
at common sites of vascular injury like in the microcirculation, secondly to be phagocyte by
macrophages cells predominantly in the spleen and liver [66].




Platelets have vital functions in immunity, wound repair and homeostasis. These functions
mainly depend on platelets concentration in blood circulation. Platelets prevent bleeding by
either sealing the hole in the blood vessel wall or by forming haemostatic plug or by liberating
several chemicals that will activate more clotting formation by breaking down more of the
platelets. The main steps for platelets action to form clot are the following:
1. Adhesion (Step 1): This reaction is mediated by release of granules and characterized by
shape change of the platelets from disc shape to spiny spheres after their adhesion to
collagen. The aggregation of the platelets in this face is reversible.
2. Aggregation (Step 2): In this step more of platelets adhere to each other and there will be
an obvious shape change of these platelets. The main factors that stimulate this step are
the chemical changes.
3. Release (Step 3): Here the aggregation caused by the dense granules released by the
platelets themselves is irreversible. In addition vasoconstriction will take place as a result
of thromboxane A2 released by the platelets.
4. Stabilization of the clot (Step 4): This is the main reaction which is responsible for the
thrombus formation,  whereby the  aggregate  platelets  will  release  factor  V that  will
accelerate  the  aggregation  of  other  platelets  and  this  will  lead  to  stabilized  clot
formation [64, 67].
From this it is clear that thrombocytopenia which is associated with decrease in platelets count
in the blood of cancer patients such as leukemic patients is considered as a very serious
problem. Thrombocytopenia prevalence in hematological patients is very high. While in case
of solid tumor, thrombocytopenia happens because of chemotherapy uses and thus the
incidence is rather low. However in some subgroups the incidence is higher than 20% and it
still remain as a serious and dangerous problem [62].
2.3.3. Thrombopoietin hormone (TPO)
It is a single 353- amino acid protein, synthesized primarily in the liver. Its level will increase
during thrombocytopenia and keep increasing in response to the decline in platelet mass. For
this reason most of the studies found that when platelets is transfused to the thrombocytopenic
patients the TPO level will decreased. TPO mainly act by increasing the numbers of megakar‐
yocyte colony forming cells (Meg-CFC), increases their ploidy, size and growth to produce
more of the platelets. Moreover, it will stimulate the hematopoietic stem cell of the bone
marrow and it has been found that high doses of TPO will lead to reactivation of the mature
platelets to some aggregation stimuli [61].
2.3.4. Main causes of thrombocytopenia
The main causes leading to occurrence of thrombocytopenia are:
1. Chemotherapy drugs.
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2. Solid cancer.
3. Blood cancer (Leukemia).
4. Spleen cancer.
5. Anemia.
6. Hemorrhage which will lead to increases loss of platelets.
7. When the rate of platelets destruction is higher than the rate of bone marrow platelets
production [57, 59, 65].
2.3.5. Role of age and gender
Repetto (2003) mentioned that anemia is highly prevalent and happened in the elderly cancer
patients who receive chemotherapy. This is specifically because their senescent cells have low
ability to repair DNA and their low mass of the hematopoietic stem cell causing slowing of
their recovery ability. Repetto also mentioned in his study that the occurrence of grade 3
thrombocytopenia is highly associated with older female suffering from breast cancer and
found that there is an association between age and gender with thrombocytopenia. While
others retrospective studies of solid tumor patients found that there is no association between
age and myelosuppression i.e., neutropenia, anemia and thrombocytopenia occurrence [68].
2.3.6. Chemotherapy and thrombocytopenia
Thrombocytopenia is a detrimental side effect of chemotherapy since it will lead to hemorrhage
from vital organ particularly the brain specifically within solid cancer patients who were
treated with chemotherapy. These chemotherapies caused thrombocytopenia by different
mechanisms either by suppressing megakaryopoiesis leading to prevention of platelets
production or by direct damaging of the platelets. Chemotherapies like antimetabolites and
alkylating agents induced severe thrombocytopenia due to their ability in causing bone
marrow suppression and specifically after the first cycle of chemotherapy [62, 69, 70, 71].
2.3.7. Mechanism of thrombocytopenia in solid cancer
The association between bleeding and thrombocytopenia in patient suffering from leuke‐
mia was first described in 1962. Later in 1878 and 1984 this was reported happening among
patient suffering from solid cancer [72]. Thrombocytopenia as a serious side effect is usually
associated with solid cancer as a result of its metastasis to bone marrow. Theoretically most
of solid tumors can metastasis to bone marrow but the most frequent are breast, lung and
prostate  cancers.  These  cancers  when  metastasized  to  bone  marrow  will  lead  to  bone
marrow suppression resulting in neutropenia and thrombocytopenia with serious morbid‐
ity and mortality (Kilickap et al.,  2007). Besides that Elting and his colleagues mentioned
that solid cancer patients are characterized by several things which are poor performance
status,  low  baseline  for  platelets  count  and  bone  marrow  metastasis.  Despite  that  the
bleeding situation among solid cancer patients remain poor compare with hematological
malignant unless all the above characteristic are all present [62].
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2.3.8. Diagnosis of thrombocytopenia
Different parameters are taken into consideration in order to diagnose thrombocytopenia
such as medical history and laboratory test. Platelets count which is considered as part of
the complete blood count (CBC) is the main key for the diagnosis of thrombocytopenia. It
measures the exact numbers of platelets in a measured volume of blood. If the test shows
low number of platelets then a careful examination for spleen and bone marrow biopsy
must  be  done  since  both  have  a  direct  association  with  thrombocytopenia  occurrence.
Usually in adults when the platelets count is less than 100,000 cell/ microliter it is consid‐
ered low but sometimes this happen without any symptoms. Other important tests which
are used to diagnose thrombocytopenia are the prothrombin time (PT),  activated partial
thromboplastin time (aPTT) and thrombin time (TT). The results of these tests play a critical
role in the diagnosis and certification of the presence of thrombocytopenia. In addition to
liver enzymes test,  renal  function test,  erythrocyte sedimentation rate (ESR),  Vit  B12  and
folic acid levels are also carried out [57, 59, 64, 65, 73, 74].
2.3.9. Grades of thrombocytopenia
The normal range of the platelets is between 150,000 and 450,000 cells per microliter of blood
(i.e., 150-450×109/ L) while thrombocytopenia could be classified into three levels as follows:
1. Mild thrombocytopenia if platelets count < 150 and ≥ 100 × 109/ L.
2. Moderate thrombocytopenia if platelets count < 100 and ≥ 50 × 109/ L.
3. Severe thrombocytopenia if platelets count < 20 × 109/ L [75, 76].
2.3.10. Clinical signs and symptoms of thrombocytopenia
There are several signs and symptoms which occasionally happen with thrombocytopenia.
These are bloody stool, dizziness, headache, hemorrhage, oral bleeding, nose bleeding, vaginal
bleeding, black stool and petechiae (reddish purple spots in the skin) [57, 58, 74].
2.3.11. Options for thrombocytopenia treatments
There are different options for thrombocytopenia treatment but the selection will mainly
depends on the etiology and severity of thrombocytopenia. Sometimes with asymptomatic
thrombocytopenia treatment is not required like that in children with viral infection. But if
thrombocytopenia incidence is because of spleen enlargement then splenectomy will be
beneficial and effective in increasing the platelets counts. While for thrombotic thrombocyto‐
penic purpura (TTP) treatment is needed since it can leads to renal failure. In case of idiopathic
thrombocytopenic purpura (ITP) the treatment depends on severity of the case and the
platelets counts. In the case of heparin induce thrombocytopenia and thrombosis (HITT) the
treatment is by stopping heparin administration. If the cause of thrombocytopenia is due to
patient’s immune system causing destruction to the platelets then the use of corticosteroids is
very effective so as to suppress immune response. While if the cause is due to chemotherapy
then the decision to either continue the treatment with low chemotherapy doses or use of
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alternative drugs or use of platelets growth factors (i.e., thrombopoietic growth factor)
(Oprelvekin, Neumega®) should be made. Recombinant human interleukin-11 (rhIL-11) will
stimulate megakaryocyte maturation and proliferation and maintain platelets production. It
has been proven by the Food and Drug Administration (FDA) that rhIL-11 is very effective in
reducing and preventing of severe thrombocytopenia as well as it will decrease the need for
platelet transfusions especially after myelosuppressive chemotherapy which could be contin‐
ue with the same doses. In the case of severe thrombocytopenia (i.e., platelet level ≤ 20,000/
µL) which is due to intensive chemotherapeutics drugs treatment of hematological and solid
cancer patients, in this case platelet transfusion is needed. At this point, patient will suffer from
severe bleeding and the laboratory tests signify that platelets transfusion is very important
and a required treatment. Platelets transfusion is one of the most important treatments for
acute and severe thrombocytopenia, but there are some limitations to its use which are: the
availability of the blood products since it must be freshly taken and used within 5 days, cost,
refractoriness, transfusion reaction and diseases transmission [57-59, 63, 76, 77].
2.3.12. Thrombocytopenia and neutropenia
Acute thrombocytopenia has been described in patients given Hematopoietic Growth Factors.
The main factor which play role in this incidence is neutropenia treatments which are either
GM-CSF and/ or G-CSF. This rapid incidence for thrombocytopenia in association with these
treatments is mainly because these treatments sometimes target the platelets or caused their
destruction. But the main mechanism which is responsible for the incidence of neutropenia
with thrombocytopenia together has not been defined yet [78].
2.4. Hypercalcemia
Hypercalcemia is a life threatening situation in which serum calcium level is elevated greater
than 10.5 mg/ dl, while albumin concentration is lower than 4 g/ dl. It is a serious problem that
occurs in about 10%-20% of all cancer patients especially lung, breast, head and neck cancer
patients. While, in hematological cancer hypercalcemia also takes place specifically in the
advanced phases of both myeloma and lymphoma. Besides that a very important point is that
hypercalcemia is mainly caused by cancer without any effect or role from anticancer treat‐
ments. So many references consider hypercalcemia as a very serious and dangerous compli‐
cation that caused a significant morbidity and mortality frequently in breast cancer patients.
It can occur in patients with and without bone metastasis and the main cause of hypercalcemia
is the pathological bone resorption. Bone resorption is caused by the secretion of cytokine like
parathyroid hormone-related protein (PTHrP) leading to activation and differentiation of
osteoclast cell. In normal condition normal breast cells also secreted PTHrP during lactation
so as to stimulate bone resorption and skeletal calcium release which will be used in milk
synthesis. In this situation hypercalcemia is asymptomatic since the elevation of calcium level
is mild, but when serum calcium elevation became very high it will leads to significant
morbidity and mortality. Hypercalcemia is highly associated with breast cancer more than
other types of cancers [78-83].




Calcium in human body has multiply functions, it is one of the major components and mineral
of the body skeleton and its concentration is maintained by influx and efflux to the extracellular
fluid from kidney, bone and gut. This vital process is regulated by two hormones which are
parathyroid hormone (PTH) and 1, 25 dihydroxyvitamin D. Serum calcium consist of calcium
bounded to albumin 37%, bounded with globulin (10%), biologically active calcium (47%) i.e.,
ionized form and calcium complex with anion (10%) (like: phosphate, citrate, bicarbonate).
The ionized serum calcium is the only form metabolically active and is regulated by homeo‐
static mechanisms [87, 90, 98]. Calcium also has other important role in regulation of the
cellular metabolism function, since it is a co-factor for many of body enzymes reactions. Also,
calcium is needed for cell adhesion, cell death, an important component of cellular electrical
current and has a very important function in muscular contraction process [84, 85].
2.4.2. Kidney role in calcium homeostasis
Kidney plays a very important role in regulation of calcium concentration in the extracel‐
lular fluid and its capacity to clear the calcium is about 600 mg per day (15 mmol/ day).
In  adult  approximately  98% of  calcium is  resorbed  by  kidney.  This  process  of  calcium
absorption is mainly controlled by PTH and 65% of total reabsorbed calcium happens at
the proximal tubules, 20-25% in the ascending loop of Henle, while only 10% in the distal
convoluted tubules [86].
2.4.3. Gut role in calcium homeostasis
The daily amount of calcium absorbed ranges between 150-200 mg/ day and this is send to the
extracellular fluid. This process of absorption is mainly regulated by 1, 25 dihydroxyvitamin
D hormone and calcium concentration in the blood circulation. Besides that the amounts of
calcium absorbed from the daily diet is affected by the amount of calcium in the diet and
presence of other dietary components which may serve to increase (lactose, fatty acid) or
decreases (oxalate, phosphate and phytate) calcium absorption. The absorption of calcium
from the daily diet varies even in healthy adult from 20% to 70%. The main parts responsible
for absorption are the ileum (65%) and jejunum (17%). This is because these parts are the longest
parts and hence the longest time calcium will be absorbed [87].
2.4.4. Bone role in calcium homeostasis
Bone consider as the main storehouse of calcium which store 99% of the body calcium. The
role of bone in calcium homeostasis is important in normal conditions since the process of bone
formation is tightly coupled with processes of bone resorption i.e., the velocity of calcium
influx and efflux between the extracellular fluid and bone. The extracellular calcium concen‐
tration will be disturbed when the rates of bone resorption increase more than the rate of bone
formation. This is seen in cases of advanced cancer diseases which caused activation of the
osteoclast cell of the bone marrow leading to increase in bone marrow destruction and increase
in calcium efflux. This mainly happy when the cancer disease metastasis to bone marrow and
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is usually consider as a catastrophic situation. Metastasis to bone marrow happens in 30% of
breast cancer patients and causing disturbances in the plasma calcium concentration. Thus it
is clear that bone play a critical role in the maintenance of serum calcium level [86, 88].
2.4.5. Main hormones responsible for calcium control
The extra cellular calcium concentration is maintained in a narrow range of 8.5-10.2 mg/ dL
(2.1-2.55 mmol/ L) by two main hormones which are:
1. Parathyroid hormone (PTH)
2. 1,25-dihydroxy-vitamin D [1,25 (OH)2 D]
Both act on the three main organs which are kidney, gut and skeleton but PTH is more
important since it regulate calcium level from minute to minute (i.e., very rapid effect), PTH
it is consists of 84 amino acid single chain polypeptides and is mainly secreted by the chief
cells of the four parathyroid glands besides the thyroid gland in the neck. PTH secretion is
regulated by the serum calcium level of the extracellular fluid. When calcium concentration
increases, the PTH secretion will be suppressed and when the calcium concentration decreases,
PTH secretion increases. PTH mainly regulates the calcium transportation between extracel‐
lular fluids and kidney, bone and gut. PTH has a direct effect on bone and plays a critical role
in increasing the rate of bone formation and turnover. Its effect on bone came from its
stimulation and activation for the osteoclast cells which will lead to increase in bone turnover
and it also increases the rate for bone formation. This effect has been found to be dependent
on the presence of other hormones like 1, 25-dihydroxyvitamin D. PTH effect on kidney will
leads to an increase in distal tubules reabsorption of calcium. Here its effect is enhanced by 1,
25-dihydroxyvitamin D, but it has no direct effect on the gut [78, 85, 88]. 1, 25 dihydroxy-
vitamin D is the major biological active metabolite of vitamin D. This steroid-like metabolite
is derived either from skin during its exposure to ultraviolet light (i.e., sun light) or from plant
ergosterol after its ingestion in the gut. It increases the absorption of calcium and phosphorus
from the gut by active transport as well as it increases the bone resorption. 1, 25 dihydroxy-
vitamin D is characterized by its slower action than PTH but it is more effective than PTH in
long term control of the serum calcium level [83, 86, 89]. Besides these two hormones, calcitonin
which is 32 amino acid peptide also is involved in calcium content. It is synthesis and secreted
by parafollicular cells of the thyroid gland. Its main action is by inhibition of the osteoclast cell
from resorption of the bone by causing their dissolution to mononuclear cells [85].
2.4.6. Causes of hypercalcemia
The main causes of hypercalcemia during solid or hematological malignancy are as follows:
1. The direct effect of cancer diseases on the bone by causing bone destruction such as with
breast cancer, lung cancer, multiply myeloma and leukemia. Hypercalcemia occurs in
about 10%-20% of all cancer patients during specific stages of their malignant diseases.
Lung and breast cancers are highly associated with hypercalcemia incidence beside head
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and neck cancer. While myeloma and lymphoma are the most common hematological
types of cancers associated with hypercalcemia.
2. Some cancers diseases lead to production of parathyroid hormone-related protein
(PTHrP) which is mainly associated with solid cancer but not with malignant cancer.
3. Some cancer diseases decrease the ability of the kidneys to remove excess calcium also
leading to decreases in the urination.
4. Dehydration due to nausea and vomiting which will lead to difficulties of the kidneys to
remove excess calcium from the blood.
5. Decreases in the movement and activity of cancer patients which will lead to breakdown
of the bone and hence increase in the release of the calcium into the blood [90-94].
2.4.7. Hypercalcemia diagnosis
Diagnosis of hypercalcemia is made based on serum calcium level and also on levels of
phosphate, chloride, PTH and alkaline phosphates. Other tests for kidney function especially
urea level, creatinine level and albumin level tests also performed because in hypercalcemia
these are elevated. Bone scan, prospective computed tomography (CT) scan for neck, chest and
magnetic resonance imaging (MRI) may help to determined whether the tumor has metasta‐
sized to the bone [95].
2.4.8. Hypercalcemia levels
Normal level of calcium in the blood ranges between 8.7 – 10.4 mg/ dl. Correct calcium level
in the blood could be determined by using the following equation:
Corrected calcium (mg/ dl) = measured calcium + ([4- albumin (g/ dl)] × 0.8).
Serum calcium ranging between 10.5 – 12.0 mg/ dl indicates mild hypercalcemia.
Moderate hypercalcemia is being diagnosed when serum calcium is between 12.0 – ≤ 14.0
mg/ dl.
Severe hypercalcemia (hypercalcemia crisis) occurs when serum calcium is higher than 14.0
mg/ dl and is associated with acute signs and symptoms [87, 90-96].
2.4.9. Signs and symptoms of hypercalcemia
Since calcium has a wide range of physiological actions so it has a myriad of clinical effects
on  multi  organs.  On  central  nervous  system  (CNS),  hypercalcemia  will  cause  fatigue,
depression, confusion, headache, difficulty in thinking and stupor. Cardiovascular system
effects manifestation will range from abnormal electrocardiogram to arrhythmias. Gastroin‐
testinal system signs will involve constipation, nausea and vomiting. Hypercalcemia will
cause impaired kidney function and as a consequence will  lead to decrease in the renal
excretion of calcium and thus increase in the severity of hypercalcemia. Dehydration, bone
pain  and  lost  of  appetite  has  also  been  observed.  The  hypercalcemia  due  to  primary
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hyperparathyroidism is usually mild or moderate and the patient will be asymptomatic or
only suffer from minor clinical signs mentioned above. While hypercalcemia occurs as a
result  of breast cancer is  usually acute or subacute and the calcium level will  be highly
elevated and many of the clinical signs mentioned above will be manifested. While mild
hypercalcemic patients  will  be asymptomatic  and hypercalcemia will  be detected fortui‐
tously during routine laboratory screening [83, 97-99].
2.4.10. Hypercalcemia treatments and options
There are different types of treatments used for hypercalcemic patients whereby some are often
use for daily cases and some others used for emergency cases of hypercalcemia:
1. Bisphosphonates (Etidronate, Clodronate and Pamidronate):
2. Plicamycin (Mithramycin)
3. Calcitonin (Calcimar®)
4. Zoledronic acid (Zometa®)
5. Glucocorticoids (Prednisone)
While for emergency cases with calcium level exceeding 13 mg/ dl the following treatments
are preferred:
1. Normal saline 200-400 ml/ hour I.V.
2. Furosemide (Lasix®) 200-400 ml/ hour [83, 86, 87, 97-99].
2.4.11. Role of age and gender
Hypercalcemia is usually seen in aged female patients more than male where the main
characteristic is the presence of hypercalcemia without any symptoms. The main cause is either
malignant disease or hyperparathyroidism [83, 86].
2.4.12. Mechanisms of hypercalcemia occurrence with malignancy
Mechanism of hypercalcemia incidence in solid cancer patients can be divided into two groups.
In the first group, hypercalcemia may or may not be associated with bone metastasis and the
main factor is the solid cancer itself since it will produce systematic circulating humoral factors
which will ultimately cause loss of calcium from the bone i.e., bone resorption. Moreover these
factors will lead to increase in calcium reabsorption from renal tubules. So this group is named
as humoral hypercalcemia of malignancy (HHM) which include lung, ovarian, head and neck,
pancreas and kidney cancer but the most frequent are the lung and head and neck cancers.
The main factors produced by the cancer cells responsible for this situation are PTH, PTH-like
factors, transforming growth factors, colony stimulating factors and leukocyte cytokines. In
the second group, hypercalcemia is mainly caused or produced by extensive bone metastasis
(i.e., extensive localized bone destruction) which include breast cancer. Breast cancer is
considered as the highest and the most frequent solid cancer associated with hypercalcemia
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caused by bone metastasis. This hypercalcemia is called local osteolytic hypercalcemia (LOH).
The main difference is that in LOH, hypercalcemia is caused by localized bone destruction
resulting from bone metastasis by the solid cancer, while in HHM the systematic humoral
factor is the sole responsible factor and that hypercalcemia is unrelated to the extent of bone
metastasis. In LOH, hypercalcemia is produced by direct effect of the solid cancer cells on the
bone i.e., by acting like osteoclast cell producing acid protease (lysosomal enzymes) and
collagens responsible for removing of mineral from bone and mainly lead to resorption of bone
matrix and causing an increase in cAMP and inhibition of microtubule assembly by agents like
colchicine. Resorption could also happened or take place independently of osteoclast cell
activity. While for hematological cancers i.e., myeloma the main causes for hypercalcemia are
increase bone resorption and glomerular filtration impairment. The main cause of hypercal‐
cemia during lymphoma is bone resorption associated with increase in absorption of calcium
from the gut [82, 86, 100].
2.4.13. Relation of hypercalcemia with nausea and vomiting
The main mechanism of hypercalcemia incidence in solid cancer is the metastasis of the cancer
to the bone. Breast cancer which is the highest type of the LOH has shown to cause bone
marrow destruction leading to hypercalcemia. Hypercalcemia will lead to many side effects
mainly nausea and vomiting and there are studies indicating that hypercalcemia is one of the
main risk factor for nausea and vomiting [16, 101].
2.5. Neurotoxicity
Neurotoxicity which induced by chemotherapy can occurs because of the direct or indirect
effect and/ or damage that chemotherapy will cause to the central nervous system (CNS) or
peripheral nervous system or any combination of these [102]. It is a critical matter to distinct
between the two components of the nervous system. The CNS consists from the brain and the
spinal cord. CNS mainly responsible for controlling neurological function of mental status,
level of consciousness, motor power, sensory function, cerebral function and cranial nerve
function. While for the peripheral nervous system it consists of peripheral nerves, this system
mainly responsible for sensing pain, temperature and sensation [103].
This side effect i.e., neurological toxicity remain as one of the major critical side effect of
chemotherapy treatment. Its clinical presentation varies significantly as a result of that it
became very difficult to confirm the diagnosis [104].
2.5.1. General signs and symptoms of neurotoxicity
Symptoms associated with neurotoxicity may include cerebellar effects i.e., (tremor, loss of
balance and fine motor movements), confusion, visual impairment, peripheral neuropathy,
somnolence and auditory [102].
It has been found that neurotoxicity problems usually temporary i.e., resolving once treatment
is completed, even so sometimes permanent neurological deficits may happened [102].
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2.5.2. Blood-brain barrier and it’s role in protecting CNS
Blood-brain barrier consider as a very efficient part of the nervous system that determine
whether a chemotherapy agent is able to reach the nervous system or not. This barrier has
the  ability  to  block  certain  chemotherapy  agents  from  entering  nervous  system  at  the
cellular level [105].  Blood-brain barrier which surrounding the CNS varies from the one
which  surrounding  the  peripheral  nervous  system,  as  a  result  of  this  variation  some
chemotherapy agents such as vincristine significantly affect the peripheral nervous system
but not the CNS. Chemotherapy agent will  produce neurotoxic effects only if  it  has the
ability to cross the blood-brain barrier [106].
2.5.3. Neurotoxicity and chemotherapy
Chemotherapy agents that significantly associated with neurotoxicity include the following:
1- Platinum compounds, 2- Taxanes, 3- Vinca alkaloid [104].
2.5.4. Factors associated with the incidence of neurotoxicity
There are many factors play role in the incidence of neurotoxicity but the most critical factors
are the following::
1. Chemotherapy doses.
2. Route of chemotherapy administration [107].
2.5.5. Other factors
The incidence of  neurotoxicity  can be related to  factors  other  than chemotherapy,  these
factors are:
1. Primary or secondary tumor deposits, which may involve the nervous system.
2. Metabolic or electrolyte imbalance which will leads to neurological disturbance.
3. Neurological deficits [108].
2.5.6. Neurotoxicity evaluation and management
Treatment used for neurotoxicity that caused by chemotherapy agents is limited. The focus of
care should be on early recognition of neurotoxicity and careful monitoring of patients at high
risk of toxicity [109]. There are various agents that either block the development and/ or
incidence of neurotoxicity that caused by chemotherapy agents. Even so the mechanisms of
action for these agents still mysterious [110]. Example for agent used as antidote for encephal‐
opathy cause by ifosfamide is the methylene blue [111], besides that amifostine and adreno‐
corticotropic hormone analogues have also been found to be an effective neuroprotective
agents. But farther investigation still required to clarifying the role of these agents in over‐
coming and/ or preventing neurotoxicity problem which leads to either delay in chemotherapy
schedule, reduction in chemotherapy doses or substitution with an alternative agent [104].




The major function of the heart is to pump the blood to the whole body to supply body organs
with adequate oxygen and nutrition they need. This process will happened by contracting
muscular walls of the left ventricle [112]. There are various factors which can leads to cardiac
injury in the cancer patients. This may happened as a result of either infiltration of metastases
to infections and/ or because of chemotherapy toxicity [112].
2.6.1. Major factors which cause cardiac damage in cancer patients
a-Cardiac tumors, b-Bacterial infections, c-Chemotherapy induce toxicity, e-Radiation induce
toxicity, f-Fungal and/ or viral infection [113, 114].
Chemotherapy effects will be classified into two types: acute and chronic effects.
2.6.2. Acute toxic effect
Acute cardiotoxicity caused by doxorubicin came from combination of factors which are:
mitochondrial changes, cellular degeneration and a loss of myocardial fibrils. The incidence
of cardiotoxicity will be either during or after doxorubicin administration, this cardiotoxicity
will leads to cardiac abnormalities which include: ST and T wave changes, sinus tachycardia,
atrial and ventricular ectopics, complete heart block, supraventricular tachycardia and
ventricular tachycardia [116, 117].
Although doxorubicin cause cardiotoxicity there is no specific treatment for this condition, but
there is only a supportive treatments. Researchers and clinicians keep on using of cardiopro‐
tective agents that allow chemotherapy agents specifically anthracycline to be used at a higher
dose without causing cardiotoxicity [114]. Example for these cardioprotective agents are
dexrazoxane and amifostine [118].
2.6.3. Chronic toxicity
This type of toxicity is one of the most common toxicity caused by doxorubicin it is character‐
ized by chronic dilated cardiomyopathy. This condition i.e., cardiomyopathy usually hap‐
pened either at late of chemotherapy cycle or shortly after the end of it [119]. Cardiomyopathy
is significantly attenuated by the chelation of iron. Moreover, cardiomyopathy has been
diagnosed among the survivors of cancer patients who have been treated with doxorubicin
during their childhood [120].
2.7. Pulmonary toxicity
It is one of the main side effects of chemotherapy, which become clinically obvious after weeks,
months or even years of termination of chemotherapy. It usually associated with several
clinical symptoms which are: dry cough, dyspnoea and progressive worsening of symptoms
with a poor prognosis for recovery [121].
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2.7.1. Chemotherapy and pulmonary toxicity
Chemotherapeutic agents will be divided into three groups, this will mainly based on their
effects on pulmonary function:
1. Hypersensitive pulmonary reaction: Bleomycin, 6-mercaptopurine, methotrexate,
mitomycin and procarbazine. This condition take place as a result of either desquamative
interstitial pneumonitis or an eosinophilic pneumonitis [122, 123].
2. Non-cardiogenic pulmonary oedema: Cyclophosphamide, cytarabine and methotrexate.
This condition will take place after few days of strating using of chemotherapy treatment.
3. Chronic pulmonary fibrosis: Bleomycin, busulfan, carmustine, cyclophosphamide,
fludarabine, ifosfamide, methotrexate and mitomycin [122, 123]. This clinical condition
will take place within months of using chemotherapy treatment.
Besides that it has been found that when mitomycin used in combination with vinca alkaloids
and/ or gemcitabine with docetaxel or when the later two agents i.e., gemcitabine and docetaxel
used alone they can cause pulmonary toxicity [124, 125, 126, 127].
2.7.2. Assessment of pulmonary function
It is very important to assess patients pulmonary function before start administration of
chemotherapy, the assessment will include the following:1- Chest X-ray 2- Lung biopsy
required to differentiate chronic fibrosis from lung metastasis [121].
2.7.3. Treatments used for pulmonary toxicity cases
Managements used for pulmonary problems i.e., toxicity will include the following: 1-
Bronchodilator, 2- Corticosteroid 3- Expectorant 4- Oxygen 5- Antibiotics 6- Nebulised saline
7- Aminophylline and theophylline [128-129].
3. Conclusion
Cancer has become a major killer in the world which almost surpasses the cardiovascular
diseases and will become the main lethal cause in this century. Although the global war against
cancer leads to remarkable gain in understanding the main molecular mechanism for the
cancer cell, this progress is still consider as slow and not enough especially in case of treatment
of common solid tumor in adults. Besides that there are so many types of serious side effects
caused by the tumor itself or because of its chemotherapy treatment.
Therefore it is an obligate for all the clinicians and physicians to focus on these main side effects
that emerged as a result of cancer itself or its treatment and working to built and develop
treatment guidelines to overcome or palliate these major side effects.
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